- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 Pathogenesis of AMD
- •1.2.1 Oxidative Damage
- •1.2.2 Lipofuscin Accumulation
- •1.2.4 Complement Mutations
- •1.2.5 Mitochondrial Damage
- •1.2.6 DICER 1
- •1.3 Treatment
- •1.3.1 Antioxidants
- •1.3.2 Visual Cycle Modulators
- •1.3.4 Neurotrophic Agents
- •1.3.5 Antiangiogenic Agents
- •1.3.5.1 Intracellular Angiogenic Factor Production
- •1.3.5.2 Extracellular Angiogenic Factors
- •1.3.6 Endothelial Cell Receptor Binding
- •1.3.7 Endothelial Cell Activation
- •1.3.8 Endothelial Cell Proliferation
- •1.3.9 Endothelial Cell Directional Migration
- •1.3.10 Extracellular Matrix Remodeling
- •1.3.11 Tube Formation
- •1.3.11.1 Loop Formation (Arteriovenous Differentiation)
- •1.3.11.2 Vascular Stabilization
- •1.4 Combination Therapy
- •1.5 Conclusions
- •References
- •2.1 Introduction
- •2.1.1 Complement Pathways
- •2.1.2 Oxidative Stress
- •2.3.1 The Mouse CNV Model
- •2.3.2 RPE Monolayers
- •2.3.3 Concept
- •2.5 Summary and Outlook
- •References
- •3.1 Introduction
- •3.2.1 Advanced Glycation End Products
- •3.2.2 Carboxyethylpyrrole
- •3.2.3 Oxidation Products of Lipofuscin
- •3.3 Summary and Conclusions
- •References
- •4.1 Introduction
- •4.2 Oxidative Stress and AMD
- •4.2.1 Basic Concepts on Oxidative Stress
- •4.2.2 Oxidative Stress in AMD
- •4.3 Malondialdehyde in AMD
- •4.3.1 Lipid Peroxidation and Malondialdehyde
- •4.3.2 Materials and Methods
- •4.3.2.1 RPE Cell Culture
- •4.3.2.2 Patients
- •4.3.2.3 MDA Assay
- •4.3.3 MDA Levels in Cultured RPE Cells and in Patients with AMD
- •4.4 Summary and Conclusions
- •References
- •5.1 Introduction
- •5.2 The Origin and Housing of RPE Lipofuscin
- •5.3 Bisretinoid Constituents of RPE Lipofuscin
- •5.3.1 A2E, Isomers and Precursors
- •5.3.4 Photooxidized Forms of Bisretinoid Pigments
- •5.4 Photoreactivity of RPE Lipofuscin
- •5.5 Photooxidation of RPE Bisretinoids
- •5.6 Bisretinoid Photodegradation
- •5.7 Potential for Cell and Tissue Damage
- •5.9 A Role for Antioxidants
- •5.10 Conclusions
- •References
- •6.1 Introduction
- •6.1.1 RPE Lipofuscin Accumulation with Age and Relation to AMD
- •6.1.2 Known Chromophores Found in RPE Lipofuscin and the Mechanism of Damage
- •6.1.3 Formation of Higher Molecular Weight Material
- •6.1.4 Current Studies and Possible Structures of Higher Molecular Weight Products
- •6.1.4.1 Lipofuscin Extracts
- •6.1.4.3 Esters and Aldehydes
- •6.2 Conclusions
- •References
- •7.2 DHA in Photoreceptor Cells
- •7.3 Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
- •7.5 Neurotrophins Trigger the Synthesis and Polarized Secretion of Neuroprotectin D1 from Human RPE Cells
- •7.6 Photoreceptor Outer Segment Phagocytosis Induces RPE Cell Survival Signaling with Associated Synthesis of NPD1 During Oxidative Stress
- •References
- •8.1 Introduction
- •8.2.1 Subcellular Localization
- •8.2.2 Expression Levels in the Retina
- •8.4.3 Regulation of RDH12 Expression and Activity During Chronic and Acute Stress
- •8.5 RDH12 and Leber Congenital Amaurosis
- •8.5.1 Inactivating Mutations of RDH12
- •8.5.2 Loss of Which RDH12 Function Induces LCA?
- •8.6 Summary and Conclusions
- •References
- •9.1 Introduction
- •9.2 GSH Metabolism: General Principles
- •9.2.2 Role of Mitochondrial GSH in Protection
- •9.2.3 GSH as a ROS Scavenger
- •9.2.4 GSH Distribution in the Retina and RPE in Health and Disease
- •9.5 Future Perspectives
- •References
- •10.1 Introduction
- •10.2 Mitochondria
- •10.2.1 Mitochondrial Biogenesis and Maintenance
- •10.2.2 Mitochondrial Removal and Degradation
- •10.3 Mitochondria and Reactive Oxygen Species
- •10.3.1 Reactive Oxygen and Nitrogen Species (ROS and RNS)
- •10.3.2 Mitochondria are a Major Source of Intracellular ROS
- •10.3.3 Other Sources of ROS in the Retina
- •10.4 The Mitochondrial Genome
- •10.4.1 Susceptibility of Mitochondrial DNA to Oxidative Stress
- •10.4.2 Mitochondrial DNA Damage
- •10.4.3 Mitochondrial DNA Repair Pathways
- •10.4.4 The Mitochondrial Base Excision Repair (mtBER) Pathway
- •10.4.6 Other Mitochondrial DNA Repair Pathways
- •10.4.6.2 Mismatch Repair (MMR)
- •10.4.6.3 Translesion Synthesis (TLS) and Damage Tolerance
- •10.4.6.4 Nucleotide Excision Repair (NER)
- •10.4.7 Intramitochondrial Localization of DNA Repair Proteins
- •10.4.8 mtDNA Damage Sensing and Signaling
- •10.4.9 Import of Nuclear Encoded DNA Repair Enzymes into the Mitochondria
- •10.5 Mitochondrial DNA Damage/Repair in the Retina and RPE
- •10.5.1 Mitochondrial DNA Damage/Repair in the RPE
- •10.5.2 DNA Repair and the Adaptive Response in the RPE
- •10.6 Pathologies Associated with Mitochondrial Dysfunction and Oxidative Stress in the Retina
- •10.6.2 Diabetic Retinopathy
- •10.6.3 Glaucoma
- •10.6.4 Uveitis
- •10.7 Pathologies Associated with Inherited Mitochondrial Disorders
- •10.8 Potential Therapeutic Options for Targeting Mitochondrial DNA Damage
- •10.8.1 Mitochondrial Biogenesis
- •10.8.2 Enhancing mtDNA Repair
- •10.8.3 Antioxidants
- •10.8.4 Autophagy
- •10.9 Conclusion
- •References
- •11.1 Introduction
- •11.2 ER Function in Normal Physiology
- •11.2.1 Major Roles of Rough ER (RER) and Smooth ER (SER)
- •11.2.2 ER and Oxidative Protein Folding
- •11.2.3 ER Resident Proteins
- •11.2.4 Potential Threat to ER Function in RPE
- •11.3 ER Response to Oxidative Stress in RPE
- •11.3.2 Initiation of UPR to Alleviate ER Burden
- •11.4 Chronic ER Stress and Oxidative Stress in the Vicious Cycle of Apoptosis Induction
- •11.5 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 Iron Homeostasis
- •12.2.1 General Iron Homeostasis
- •12.2.2 Iron Import into the Retina
- •12.2.2.1 Transferrin Mediated Transport
- •12.2.2.3 Dexras
- •12.2.3 Iron Storage
- •12.2.3.1 Ferritin
- •12.2.3.2 Mitochondrial Ferritin
- •12.2.4 Iron Export
- •12.2.4.1 Ceruloplasmin
- •12.2.4.2 Hephaestin
- •12.2.4.3 Ferroportin and Hepcidin
- •12.3 Disruption of Iron Homeostasis and Oxidative Damage
- •12.4 Retinal Disorders Resulting from Abnormal Retinal Iron Metabolism
- •12.4.2 Aceruloplasminemia
- •12.4.3 Hemochromatosis
- •12.4.4 Friedreich’s Ataxia
- •12.4.6 Siderosis
- •12.4.7 Subretinal Hemorrhage
- •12.5 Potential Therapeutics
- •References
- •13.1 Vascular Endothelial Growth Factor and Its Functions in the Retina
- •13.1.1 VEGF Isoforms
- •13.1.2 VEGF Functions
- •13.1.3 Cells Secreting VEGF in the Retina
- •13.1.3.1 Retinal Pigment Epithelium
- •13.1.3.2 Müller Cells
- •13.1.3.3 Astrocytes
- •13.1.3.4 Pericytes
- •13.1.4 VEGF Receptors and VEGF Induced Signal Transduction
- •13.1.4.1 VEGF Receptors
- •VEGFR-1
- •VEGFR-2
- •Neuropilin
- •Heparan Sulfate Proteoglycan
- •13.2 Regulation of VEGF Expression
- •13.2.1 Transcriptional Regulation
- •13.2.2 Translational Regulation
- •13.2.3 Hypoxia Induced VEGF Regulation
- •13.2.4 Posttranslational Regulation
- •13.2.5 Autocrine VEGF Regulation
- •13.2.6 Pathological VEGF Production
- •13.2.6.1 Hyperglycemia
- •13.2.6.2 Oxidative Stress
- •13.2.6.3 Cytokines
- •13.2.6.4 Endoplasmic Reticulum
- •13.2.6.5 Additional Factors
- •13.3.1 Pegaptanib
- •13.3.2 Bevacizumab and Ranibizumab
- •13.3.4 siRNA
- •13.3.5 Small Molecule Tryrosine Kinase Inhibitors
- •13.3.6 Other Inhibitors
- •13.4.2 Interaction of VEGF Antagonists with Antiangiogenic VEGFxxxb
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2 NADPH Oxidase and Redox Signaling
- •14.3 Expression of NADPH Oxidase Subunit p22phox in the Retina
- •14.4 NADPH Oxidase and Choroidal Neovascularization
- •14.5 Implication and Therapeutic Potential of NADPH Oxidase in Development of CNV
- •14.6 Summary and Future Perspective
- •References
- •15.1 Introduction
- •15.2 Aging
- •15.3 Deposition and Formation of Oxidized LDL
- •15.6 Treatments for AMD
- •15.7 Conclusions
- •References
- •16.1 Introduction
- •16.2 HGF and Its Receptor (MET)
- •16.2.1 Production and Secretion of HGF
- •16.2.2 MET and Biological Effects of HGF
- •16.2.3 Signaling Pathways of HGF
- •16.2.4 HGF and MET in Disease States
- •16.4 HGF Protects RPE Cells from Oxidative Stress
- •16.4.1 HGF and RPE Cells
- •16.4.2 HGF Promotes Cell Survival
- •16.4.3 HGF Protects Cells from Oxidative Stress
- •16.4.4 HGF Protects RPE Cells from Hydrogen Peroxide
- •16.4.5 HGF Protects RPE Cells Against Ceramide Damage
- •16.4.6 HGF Protects RPE Cells from Glutathione Depletion
- •References
- •17.1 Introduction
- •17.2.1 Fundoscopy
- •17.2.2 Histology
- •17.2.3 Ultrastructure
- •17.3.1 Lipofuscin (A2E)
- •17.3.3 HtrA2/Omi
- •References
- •18.1 Introduction
- •18.2 Systemic Markers of Oxidative Stress
- •18.2.1 Redox Status
- •18.2.2 DNA Damage
- •18.2.4 Lipid Peroxidation
- •18.3 Defenses Against Oxidative Stress
- •18.3.1 Antioxidants
- •18.3.2 Antioxidant Enzymes
- •18.4 Oxidative Stress and Genetics
- •18.4.1 Antioxidant Enzyme Polymorphisms
- •18.5 Environmental Exposures and Oxidative Stress
- •18.5.1 Smoking
- •18.5.2 Light Exposure
- •18.6 AMD Treatments and Oxidative Stress
- •18.8 Summary and Conclusions
- •References
- •19.1 Characteristics of Cerium Oxide Nanoparticles
- •19.3 Mechanism of Nanoceria Uptake, Internalization, and Localization in the Cell
- •19.4 Biological Effect, Functional Mechanism, and Applications
- •19.4.1 Bacteria
- •19.4.2 Plants
- •19.4.3 Medical Usage
- •19.4.3.1 Radioprotectants
- •19.4.3.2 Burn Treatment
- •19.4.4 Medical Imaging
- •19.5 Stability of Nanoceria Under storage Conditions and Its Longevity in the Cell In Vivo
- •19.6 Oxidative Damage Results in Neurodegeneration
- •19.7.1 Prolong Cellular Life Span
- •19.7.2 Cardioprotection
- •19.8 Treatment of Ocular Disorders
- •19.8.1 Methodology
- •19.8.2 Prevention of Light Damage and Rescue of Retinal Function
- •19.8.3 Treatment of Degenerative Ocular Diseases
- •19.8.4 Treatment of Ocular Neovascular Diseases
- •19.9 Toxicity and Environmental Impacts
- •19.10 Conclusion and Future Directions
- •References
- •20.1 Introduction
- •20.2 Retinal Progenitor Cells (RPCs) Are Multipotential
- •20.4 Therapeutic Strategies for Repair and Regeneration of Retinal Cells: Repair of the RPE
- •20.5 Challenges for RPE Stem Cell Therapy
- •20.6 Characterization of RPE-Like Cells Derived from BMDCs
- •20.7 BMDCs Differentiate into Retinal Cells
- •20.8 Summary and Future of Cell Therapy for Dysfunctional RPE
- •References
- •21.1 Introduction
- •21.2 Carotenoids in Retinal Diseases
- •21.4 Polyphenols or Phenolic Esters in Retinopathies
- •21.4.1 Caffeic Acid Phenethyl Ester
- •21.4.2 Catechin
- •21.4.3 Curcumin
- •21.4.4 Proanthocyanidin
- •21.4.5 Resveratrol
- •21.5.2 Sulforaphane
- •21.6 Vitamins in Retinopathies
- •21.6.1 Vitamin A
- •21.7 Perspectives
- •References
- •22.1 Introduction
- •22.1.1 Neuroprotection as a Strategy for Retinal Degenerative Disease
- •22.2.2 Putative Mechanisms of CNS Neuroprotection
- •22.3.9 Conclusion
- •22.4 Mechanisms of Retinal Protection
- •22.4.1 Insights from In Vitro Models
- •22.5.1 Background to the Disease and the Associated Preclinical Data
- •22.5.2 Overview of the Clinical Development Program
- •References
- •23.1 Introduction
- •23.2 Pathogenesis
- •23.4 Pegaptanib
- •23.5 Bevacizumab
- •23.6 Ranibizumab
- •23.7.1 Ranibizumab
- •23.7.2 Bevacizumab
- •23.8 Comparison of AMD Treatment Trials (CATT)
- •23.9 Management of Nonresponders
- •23.11 Conclusion
- •References
- •24.1 Introduction
- •24.2 Rationale for Combination Therapy
- •24.3 Supporting Evidence for Combination Therapy
- •24.4 Currently Applied Combination Therapies
- •24.5 Challenges for Combination Therapy
- •References
- •25.1 Human Endothelial Progenitor Cells
- •25.3 Function of EPCs
- •25.3.1 EPCs in Vascular Repair and Neovascularization
- •25.4 EPCs in Diabetes
- •25.4.1 EPC as a Biomarker in Diabetes
- •25.4.1.1 EPC Dysfunction in Diabetes
- •25.4.1.2 Oxidative Stress and EPC Dysfunction in Diabetes
- •25.4.1.3 Therapeutic Angiogenesis by EPCs in Diabetic Retinopathy
- •25.5 Conclusion
- •References
- •26.1 Introduction
- •26.1.1 Nitric Oxide
- •26.1.2 Nitric Oxide Regulation
- •26.1.3 Nitric Oxide in Normal and Pathophysiological Conditions
- •26.2 Retinal Vascular Diseases: The Role of iNOS
- •26.2.1 Nitric Oxide in Diabetic Retinopathy
- •26.2.2 iNOS in Diabetic Retinopathy
- •26.2.2.2 iNOS and Leukocyte Adhesion to Retinal Vessels
- •26.2.2.3 iNOS and Retinal Cell Death
- •26.2.3 Proliferative Retinal Diseases
- •26.2.3.1 iNOS and Proliferative Retinal Diseases
- •26.2.3.2 iNOS and Ocular Neovascularization in Retinal Vascular Diseases
- •26.3 Conclusions
- •References
- •27.1 Introduction
- •27.2 Animal Model
- •27.2.1 LHP Preparation and Injection Procedure
- •27.2.2 Acridine Orange Digital Fluorography
- •27.3 Experimental Results
- •27.3.1 Leukocyte Rolling
- •27.3.2 Accumulated Leukocytes in the Retinal Microcirculation
- •27.3.3 Diameter of Major Retinal Vessels
- •27.3.4 SOD Treatment
- •27.4 Discussion
- •27.5 Conclusions
- •References
- •28.1 Introduction
- •28.1.2 Metabolism and Balance in Generation and Quenching of ROS
- •28.2 Role of Oxygen Concentration on Generation of ROS in the Developing Retina
- •28.3.1 Perinatal Considerations
- •28.3.2 Neonatal Considerations
- •28.3.2.1 Polyunsaturated Fatty Acids in Retina and Brain
- •28.3.2.2 Increased Oxidation
- •28.3.2.3 Reduced Antioxidant Enzyme Systems
- •28.3.3 Environmental Stimuli
- •28.3.3.1 Light
- •28.3.3.2 Oxygen Changes in Development and Prematurity
- •28.3.3.3 Nutrition
- •28.3.3.4 Effect of Blood Transfusions on Oxidative Stress in Prematurity
- •28.4 Evidence from Animal Models
- •28.4.1 Background
- •28.4.2 Effects of Hypoxia on Bioenergetic Oxygen Sensor Mechanisms and Related to ROP
- •28.4.2.2 NADPH Oxidase
- •28.4.2.3 Cytochrome p450 Monooxygenases (CYP)
- •28.4.2.4 eNOS
- •28.4.2.5 Heme Oxygenase
- •28.4.2.6 Metabolic Effects of Hypoxia
- •28.4.3 Laboratory Evidence of Antioxidants on Animal Models of ROP
- •28.5 Clinical Studies of Antioxidants on ROP
- •28.6 Genetics
- •28.7 Summary
- •References
- •29.1 Introduction
- •29.1.1 Oxidative Stress in Glaucoma
- •29.1.2 Oxidative Stress in Diabetic Retinopathy
- •29.1.3 Oxidative Stress in Age Related Macular Degeneration
- •29.1.4 Vascular Endothelial Growth Factor
- •29.1.5 VEGF Mediated Neuroprotection
- •29.1.6 Mechanisms of VEGF Protection Against Oxidative Stress
- •References
- •30.1 Introduction
- •30.1.1 Oxidation and Oxidative Stress
- •30.1.2 Reactive Oxygen Intermediates
- •30.1.3 ROIs and Cellular Retinal Damage
- •30.1.4 Light, Cellular Retinal Damage and AMD
- •30.1.5 Carotenoids
- •30.1.6 Chemistry of Carotenoids: Basic Structural Components
- •30.2 Building Blocks
- •30.3 The Polyene Backbone
- •30.5 Terminal Groups
- •30.5.1 Source of Macular Carotenoids
- •30.5.2 Macular Carotenoids: The Origins of Macular Pigment
- •30.5.3 The Functions of the Macular Carotenoids as Macular Pigment for AMD
- •30.6 Antioxidant Properties
- •30.6.1 The Functions of the Macular Carotenoids as Macular Pigment for Visual Performance
- •References
- •31.1 Introduction
- •31.2 Composition and Distribution
- •31.3 Selective Uptake and Deposition Process of MP
- •31.4 Measurements
- •31.4.1 Heterochromatic Flicker Photometry
- •31.4.4 Resonance Raman Spectroscopy
- •31.5 Antioxidant Mechanism of MP and Its Relation to Retinal Health and Disease
- •31.5.1 Oxidative Stress in Human Retina and the Antioxidant Mechanism of MP
- •31.5.2 MP in Human Eye Health and Disease
- •31.5.2.2 MacTel
- •31.5.2.3 Acuity
- •31.6 Ocular Carotenoid Supplementation Studies
- •31.7 Conclusion
- •References
- •Index
- •About the Authors
7 Docosahexaenoic Acid Signalolipidomics in the Homeostatic ModulationÉ |
143 |
mitochondrion, where superoxide (O2−2) is generated from complexes I and III and quickly dismutated to H2O2 and oxygen by superoxide dismutase [23]. It follows, therefore, that mitochondrial function that is compromised is a central component of the impairments seen in degenerative disease [11, 24, 25]. One of the most prevalent ROS in cells is H2O2; its biological function is characterized by its reactivity, redox potential,relativestabilityincells,anditsabilitytotraversemembranes[19,20,26,27]. Furthermore, H2O2 is a second messenger modulating the homeostatic redox state [28] and the actions of platelet-derived growth factor (PDGF) [29, 30], epidermal growth factor (EGF) [31], and endocrine regulation. H2O2 detoxiÞcation is accomplished by enzymatic (catalase, glutathione peroxidases, peroxiredoxins) and nonenzymatic (glutathione, vitamins A, C, and E, and bilirubin) mechanisms.
In retinal degeneration, clinical evidence reveals that photoreceptor cell death takes place over the course of several years. The constant rebuilding of photoreceptor outer segments requires molecular building blocks, energy, and an environment suitable for promoting cellular integrity. Photoreceptors shed outer segment tips which are then phagocytized daily, in an intermittent, circadian fashion by mammalian RPE cells [32Ð34]. The length of the outer segments remains constant due to the highly regulated biogenesis of outer segment membrane components in inner segments, and the phagocytosis of these shed tips at an equal, compensatory rate. During photoreceptor outer segment renewal, proteins turn over and are continually replaced [35]. Therefore, it is critical to identify early prosurvival, antiinßammatory signaling mechanisms essential for maintaining photoreceptor cell integrity as this may lead to novel therapeutic interventions for halting or slowing disease progression.
7.2DHA in Photoreceptor Cells
The lipid milieu of the outer segments membranes in which rhodopsin and other proteins perform their functions is distinguished by phospholipids rich in DHA and in omega-3 fatty acid derivatives longer than C22. A salient characteristic of photoreceptor outer segments is the very high concentration of omega-3 fatty acid family members of which all are essentially esteriÞed in phospholipids [1, 3, 36]. In some phospholipids, there are two omega-3 fatty acids esteriÞed at both the sn-1 and sn-2 positions of the same glycerol backbone yielding the supraenoic or supraene molecular species [37Ð40]. In addition, identiÞcation of di-docosahexaenoyl diglycerides in the amphibian retina [41, 42] and the observation that DHA is enriched in phosphatidic acid of the retina [43, 44] suggests that the composition, metabolism, and function of supraenoic molecular species of phospholipids are important in photoreceptor organization and function. Supraenoic molecular species of phospholipids represent 31% of phosphatidylcholine, 52% of phosphatidylserine, and 20% of phosphatidylethanolamine in photoreceptor discs [37]. The supraenoic phosphatidylcholines that contain DHA at position sn-2 and the 24:6Ð36:6 elongation products of the omega-3 fatty acid family series at position sn-1 are tightly bound to
144 |
N.G. Bazan and A. Halabi |
rhodopsin [45]. These very long-chain fatty acids at sn-1 may ÒcurlÓ and restrict rhodopsin motion, likely forming a disc membrane domain that does not favor the classical bilayer membrane organization [45]. In fact, phospholipids containing DHA provide a favorable environment within which G-protein-coupled events can occur [45]. Another point of interest is the physiologically selective enrichment of DHA in phosphatidylserine of neural cells resulting in the positive modulation of Akt survival signaling [46, 47]. These aspects of DHA content are not mutually exclusive and might indicate speciÞc functions for membrane DHA.
Under normal conditions, DHA is retained and protected from peroxidation. However, in experimental models of retinal degeneration [48], when lipid peroxidation takes place, perturbations of photoreceptor function, damage, and cell death occur. In UsherÕs syndrome [49, 50] and several forms of RP [49, 51Ð55], a decrease in the blood content of DHA has been found. This implies that retinal impairment may be a consequence of decreased DHA supply and a decreased availability of DHA to photoreceptors. However, the relationship between decreased DHA in the blood supply, disease initiation and progression remains unclear. Indeed, rats overexpressing rhodopsin mutations homologous to human RP display decreased amounts of DHA in photoreceptors [56]. This Þnding might represent a retinal response to metabolic stress, whereby decreasing the amount of the major target of lipid peroxidation DHA, contributes to photoreceptor protection [56]. Moreover, constant-light- mediated retinal degeneration causes a loss of DHA from photoreceptors. Still, rats reared in bright cyclic light are protected from both photoreceptor loss and degeneration, thus suggesting the potential for an adaptive, plastic response [57].
Is the shortage of DHA in the blood of RP [55, 58, 59] and UsherÕs syndrome patients [49, 50] reßected in the relationship between very-long-chain, DHA-derived acyl groups and rhodopsin? Or, as shown in experimental retinal degeneration, is the peroxidation of DHA, which is closely associated with rhodopsin, impairing the function of this protein? Although these questions have not yet been answered, we do know that DHA promotes survival [60] and inhibits apoptosis [61] of photoreceptors. Similarly, in an AlzheimerÕs disease (AD) mouse model, DHA exerts neural protection [62] and several studies have shown neuroprotective properties of DHA [1, 3, 46, 60, 61].
7.3Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
RPE cells, the most active phagocytes of the body, are derived from the neuroectoderm and support photoreceptor cells by participating in the daily shedding, internalization, and degradation (phagocytosis) of the tips of the photoreceptor outer segments (membrane discs). In mammals, circadian shedding and phagocytosis of one entire rod outer segment (ROS) has been calculated to be complete after 10 days [34, 35]. In rhesus monkeys, every RPE cell makes contact with 20Ð45 photoreceptor tips [63], whereas each contacts 23 photoreceptors in the human macula [64]. An RPE cell interacts
7 Docosahexaenoic Acid Signalolipidomics in the Homeostatic ModulationÉ |
145 |
Fig. 7.1 Biosynthesis of NPD1. A membrane phospholipid containing a docosahexaenoyl chain in sn-2 is hydrolyzed by a phospholipase A2, generating a free (unesteriÞed) DHA. The carbons of DHA are numbered and the omega-3 (n-3) tail highlighted. Lipoxygenation is then followed by epoxidation and hydrolysis to generate NPD1. (Republished from Bazan [150], with permission. The Association for Research in Vision and Ophthalmology is the copyright holder)
through its apical side with the ROS and phagocytizes about 10% of the photoreceptor outer segments daily. This immense task is comparable to engulÞng and degrading (phagolysosomal processing) the equivalent of 5Ð10 red blood cell membranes per day. Outer segment phagocytosis is an intricate process that engages RPE cell-surface receptors to recognize, bind to, and internalize photoreceptor tips [32, 65, 66]. The cells undergo cytoskeletal rearrangements, genes are induced [67], lysosomeÐphagosome fusion takes place, and recycling of retinol and DHA is initiated [3, 68]. Consequently, ROS renewal occurs, resulting in an outer segment that is unmodiÞed in length because, as the discs at the tips are phagocytized, membrane biogenesis from the inner segment precisely replaces the amount of membrane removed. RPE cells perform other roles such as transport and reisomerization of bleached visual pigments, synthesis and secretion of neurotrophic factors, and contribution to the integrity of the barrier between choroidal blood and the photoreceptors. In this way, RPE cells display complex, pleiotropic behavior capable of resembling a variety of cell types that range from macrophages to classic cuboidal epithelial cells and glial cells.
One response of the RPE cell to oxidative stress is induction of NPD1 synthesis [69] (Fig. 7.1). The name ÒNPD1Ó is based upon its neuroprotective bioactivity and
146 |
N.G. Bazan and A. Halabi |
potent ability to inactivate proapoptotic and proinßammatory signaling in oxida- tive-stressed RPE cells and the brain. ÒD1Ó refers to NPD1 being the Þrst identiÞed neuroprotective mediator derived from DHA.
Early studies demonstrated that the retina forms mono-, di-, and trihydroxy derivatives of DHA whose syntheses are blocked by lipoxygenase inhibitors. This suggests an enzymatic process of a lipoxygenase nature. Before the stereochemistry and bioactivity of DHA-oxygenated derivatives were deÞned, it was proposed that lipoxygenase products might be neuroprotective; it was at this time the name ÒdocosanoidsÓ was suggested [70, 71]. Upon the advent of liquid chromatography, photodiode array, electrospray ionization, and tandem mass spectrometry-based lipidomic analysis, a collaboration between the group of Charles Serhan (Harvard Medical School) and our group identiÞed oxygenation pathways for the synthesis of the docosanoid NPD1 during brain ischemiaÐreperfusion [72] and RPE cells challenged by oxidative stress, interleukin (IL)-1b or calcium inophore [69]. NPD1 is formed from free (unesteriÞed) DHA and released from membrane phospholipids by phospholipase A2 (PLA2). Photoreceptors and RPE cells contain phospholipids richly endowed with DHA in the form of docosahexaenoylor DHA-elongated fatty acylchains; however, similar to unesteriÞed arachidonic acid, they have an undetectable quantity of unesteriÞed (free) DHA under basal, unstimulated conditions [73Ð77]. This means that the pool size of unesteriÞed DHA is tightly regulated at the levels of its production by PLA2, its removal (e.g., reacylation), and its peroxidation.
Free DHA that is to be incorporated into membrane phospholipids Þrst becomes activated as docosahexaenoyl-coenzyme A, enabling it to be channeled through acyltransferases that will ultimately incorporate it into phospholipids [78Ð81]. Thus the RPE cell modulates the uptake, conservation, and delivery of DHA to photoreceptors [71] and utilizes a speciÞc DHA-phospholipid pool as a precursor for the pathway leading to NPD1 synthesis. NPD1 is a stereospeciÞc mediator that is synthesized after DHA is released through DHA oxygenation by PLA2 and subsequent 15-lipoxygenase-like activity [69]. Given the crucial roles they play, it is essential for the nature of these enzymes to be precisely deÞned. In postmortem Alzheimer Disease brains, it was found that cPLA2a and 15 lipoxygenase-1 expression changes correlated with NPD1-decreases in the CA1 region of the hippocampus [82]. In ARPE-19 cells, which are spontaneously transformed human RPE (hRPE) cells, interleukin (IL)-1b, oxidative stress, or the Ca2+ ionophore A23187 activate synthesis of NPD1 [69]. Therefore, NPD1 might act in an autocrine fashion and/or diffuse through the interphotoreceptor matrix (IPM) to act as a paracrine mediator of photoreceptor cells and/or MŸller cells [3].
7.4Antiapoptotic and Anti-inflammatory Bioactivity of NPD1
The pathways modulated by NPD1 have just begun to be deÞned. For example, NPD1 induces differential changes in the expression of the Bcl-2 family of proteins by upregulating protective Bcl-2 proteins (Bcl-2, Bcl-xL, and Bß-1/A1) and
7 Docosahexaenoic Acid Signalolipidomics in the Homeostatic ModulationÉ |
147 |
attenuating the expression of those that challenge cell survival (e.g., Bax, Bad, Bid, and Bik). An NPD1-mediated, coordinated regulation of the availability of Bcl-2 proteins for subsequent downstream signaling might be crucial for cell survival [69, 82]. Translational or post-translational events may also integrate a response to counteract oxidative stress. Bcl-xL is a major antiapoptotic Bcl-2 protein required for cell survival; however, phosphorylation at residue Ser-62 renders this protein proapoptotic. The serine/threonine protein phosphatase 2A (PP2A) is a key regulator of Bcl-xL phosphorylation at residue Ser-62 in the ARPE-19 cell. Bcl-xL phosphorylation is increased under oxidative stress with the application of okadaic acid, a PP2A inhibitor, or the depletion of the catalytic subunit of PP2A (PP2A/C) by small interfering RNA. PP2A/C colocalizes and interacts with S62Bcl-xL in cells undergoing OS. Disruption of PP2A/C exacerbates OSÐinduced apoptosis. NPD1 downregulates OS -induced phosphorylation of Bcl-xL by increasing protein phosphatase activity and increasing the association of PP2A/C with S62Bcl-xL and total Bcl-xL [83]. It also attenuates apoptosis induced by OS and PP2A/C knockdown. NPD1 enhances the heterodimerization of Bcl-xL with the proapoptotic protein Bax and modulates the activation of Bcl-xl through dephosphorylation by PP2A. This suggests a coordinated, NPD1-mediated regulation of cell survival in response to OS [83].
The Bcl-2 family of proteins regulates apoptotic signaling at the level of mitochondria and the endoplasmic reticulum. Caspase-3, a downstream effector of proapoptotic and antiapoptotic Bcl-2 proteins, is activated as a consequence of mitochondrial cytochrome c release into the cytoplasm and activation of the apoptosome [84]. In RPE cells, cleavage of endogenous substrates by caspase-3 is enhanced by oxidative stress, as indicated by increased accumulation of poly(ADP-ribose) polymerases (PARPs). NPD1 inhibits caspase-3 activation when added at the onset of oxidative stress [69], this effect is interpreted as a downstream consequence of NPD1 modulation of the premitochondrial Bcl-2 proteins. It is signiÞcant that DHA itself inhibits apoptosis in parallel with a time-dependent formation of NPD1. Interestingly, the potency of DHA for cytoprotection is much higher than that of added NPD1 [69] suggesting that NPD1 might exert its action near the subcellular site of its synthesis. It is important to note that these actions of DHA cannot be mimicked by other PUFAs (e.g., 20:4,n-6). Other NPD-like mediators might potentially participate in promoting RPE cell survival in an attempt to cope with the multiplicity of signaling pathways that are impacted by RPE cells or neurons confronted by oxidative stress. DNA array-based human genome expression proÞling has revealed that NPD1 turns off several proinßammatory and proapoptotic genes and induces antiapoptotic genes in human neural progenitor cells [82]. Remarkably, DHA, and even more so NPD1, mediate opposite changes from those elicited by the amyloid b peptide Ab42 which enhances expression of genes encoding cytokine exodus protein-1 (CEX-1), IL-1b, tumor necrosis factor alpha (TNF-a), and cyclooxygenase-2 (COX-2), in addition to the TNF-a-inducible proinßammatory element B94 [82]. These observations further suggest that NPD1 induces a gene expression program in both RPE and neural cells that is neuroprotective
